JP2005507883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507883A5 JP2005507883A5 JP2003528545A JP2003528545A JP2005507883A5 JP 2005507883 A5 JP2005507883 A5 JP 2005507883A5 JP 2003528545 A JP2003528545 A JP 2003528545A JP 2003528545 A JP2003528545 A JP 2003528545A JP 2005507883 A5 JP2005507883 A5 JP 2005507883A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- amount
- water
- gastric
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/955,801 | 2001-09-19 | ||
| US09/955,801 US20030235628A1 (en) | 2001-09-19 | 2001-09-19 | Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| PCT/US2002/022229 WO2003024449A1 (en) | 2001-09-19 | 2002-07-12 | Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012091625A Division JP2012176955A (ja) | 2001-09-19 | 2012-04-13 | 医薬化合物を酸性環境から保護するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005507883A JP2005507883A (ja) | 2005-03-24 |
| JP2005507883A5 true JP2005507883A5 (enExample) | 2009-04-16 |
| JP5017763B2 JP5017763B2 (ja) | 2012-09-05 |
Family
ID=25497361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003528545A Expired - Fee Related JP5017763B2 (ja) | 2001-09-19 | 2002-07-12 | 医薬化合物を酸性環境から保護するための医薬組成物 |
| JP2012091625A Pending JP2012176955A (ja) | 2001-09-19 | 2012-04-13 | 医薬化合物を酸性環境から保護するための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012091625A Pending JP2012176955A (ja) | 2001-09-19 | 2012-04-13 | 医薬化合物を酸性環境から保護するための医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030235628A1 (enExample) |
| EP (1) | EP1429766A1 (enExample) |
| JP (2) | JP5017763B2 (enExample) |
| CA (1) | CA2460987A1 (enExample) |
| MX (1) | MXPA04002627A (enExample) |
| WO (1) | WO2003024449A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| KR101173580B1 (ko) * | 2003-03-18 | 2012-08-13 | 코와 가부시키가이샤 | 제산제 조성물 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2005213472A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7391015B2 (en) * | 2005-06-03 | 2008-06-24 | Mds Analytical Technologies | System and method for data collection in recursive mass analysis |
| AU2007205893A1 (en) * | 2006-01-19 | 2007-07-26 | The Curators Of The University Of Missouri | Pharmaceutical composition comprising a protein pump inhibitor and protein component |
| AU2007278986B2 (en) * | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
| US20080166423A1 (en) * | 2007-01-06 | 2008-07-10 | Renjit Sundharadas | Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity |
| EP2523654A4 (en) * | 2010-01-11 | 2014-08-06 | Mohamed Shafee Muneera | IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10383825B2 (en) | 2015-08-13 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
| CN110840866A (zh) * | 2018-08-20 | 2020-02-28 | 成都新睿泰康科技有限公司 | 一种细辛脑药物组合物及其在防治神经退行性疾病方面的应用 |
| US11000540B1 (en) * | 2019-11-22 | 2021-05-11 | Al Siamon | Treatment for reducing adverse events including chemotherapy discomfort and other conditions |
| US11253595B2 (en) * | 2019-11-22 | 2022-02-22 | Al Siamon | Treatment for reducing adverse events including chemotherapy discomfort and other conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB747293A (en) * | 1953-04-14 | 1956-04-04 | Abbott Lab | Therapeutic preparations containing erythromycin stearate |
| GB745493A (en) * | 1953-11-13 | 1956-02-29 | Macleans Ltd | Improvements in or relating to the preparation of stomach powders comprising one or both of the carbonates of magnesium and calcium and aluminium hydroxide |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| JPS6396126A (ja) * | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| AU7375598A (en) * | 1997-05-09 | 1998-11-27 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| AU2878801A (en) * | 1999-10-01 | 2001-05-10 | Natco Pharma Limited | An improved pharmaceutical composition and a process for its preparation |
| GB2358136A (en) * | 2000-01-15 | 2001-07-18 | Univ Montfort | A medicament for the treatment of equine oral stereotypies using a pH regulator |
| US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
| US6544556B1 (en) * | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
-
2001
- 2001-09-19 US US09/955,801 patent/US20030235628A1/en not_active Abandoned
-
2002
- 2002-07-12 CA CA002460987A patent/CA2460987A1/en not_active Abandoned
- 2002-07-12 MX MXPA04002627A patent/MXPA04002627A/es active IP Right Grant
- 2002-07-12 WO PCT/US2002/022229 patent/WO2003024449A1/en not_active Ceased
- 2002-07-12 EP EP02750005A patent/EP1429766A1/en not_active Withdrawn
- 2002-07-12 JP JP2003528545A patent/JP5017763B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-14 US US12/558,725 patent/US20100234430A1/en not_active Abandoned
-
2012
- 2012-04-13 JP JP2012091625A patent/JP2012176955A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507883A5 (enExample) | ||
| JP2773959B2 (ja) | 大腸内放出性固形製剤 | |
| KR100780156B1 (ko) | 맛 차폐용 코팅 조성물 | |
| JP3725542B2 (ja) | ピコサルフェート剤形 | |
| CN1174740C (zh) | 掩味的药用液体制剂 | |
| JP2008143914A (ja) | 炎症性腸疾患を治療するための医薬組成物 | |
| JPH10508835A (ja) | 医薬組成物 | |
| JP3633936B2 (ja) | センナ剤形 | |
| PT93029A (pt) | Processo para a preparacao de uma composicao contendo acido 5-(2,5- dimetilfenoxi)-2,2-dimetil-pentanoico (gemfibrozilo) de libertacao modificada | |
| CA2415643A1 (en) | Pharmaceutical composition for oral use with improved absorption | |
| UA73092C2 (uk) | Таблетка з ентеросолюбільним покриттям і спосіб її приготування | |
| JPH10147517A (ja) | 高められた崩壊特性を有するフイルムコーテイングされた錠剤組成物 | |
| EA003512B1 (ru) | Желудочная и/или дуоденальная клейкая лекарственная форма | |
| CN100528232C (zh) | 包含酸不稳定活性成分的混悬液形式的药物制剂 | |
| KR20040086364A (ko) | 조성물 내에서의 또는 조성물에 관련된 개선책 | |
| JP2014240435A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| RU2007120753A (ru) | Порошкообразная антацидная фармацевтическая композиция, содержащий ее фармацевтический препарат и способ ее получения | |
| ES2351067T3 (es) | Composiciones farmacéuticas fáciles de tragar, que no provocan una sensación desagradable en la boca y que comprenden partículas con un ingrediente activo. | |
| WO1999000112A1 (en) | Sucralfate-containing composition and process for the preparation thereof | |
| JP3592723B2 (ja) | 非崩壊・持続性カプセル製剤 | |
| WO2019115501A1 (en) | Oral gastroretentive sustained-release pharmaceutical formulation | |
| JPH04264022A (ja) | 下部消化管放出型経口製剤 | |
| KR0171413B1 (ko) | 젬피브로질 제제 | |
| CA2472449A1 (en) | Pharmaceutical composition for oral use with improved absorption | |
| JPH1171285A (ja) | スクラルファート含有組成物及びその製造方法 |